ArticleMolecular biomedicine2026
Reduced cartilage matrix stiffness in temporomandibular joint osteoarthritis impairs the functions of superficial zone chondrocytes via downregulation of CREB5-PLPP3 signaling.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Temporomandibular joint (TMJ) plays critical roles in the movement of mandible. TMJ osteoarthritis (TMJOA) leads to pain and limited jaw function. Histologically, TMJOA causes cartilage degradation and a reduction in extracellular matrix (ECM) stiffness. The superficial zone chondrocytes (SZC) contribute in the regeneration of the condylar fibrocartilage in TMJ, while their responses to the softened ECM remains unclear. Here, we showed that the ECM stiffness was decreased in the superficial zone cartilage of TMJOA patients and rat models. Single-cell RNA sequencing demonstrated the diminished phospholipid phosphatase 3 (Plpp3) expression, impaired migration, and ECM secretion, as well as the down-regulated PI3K-AKT pathway of SZC in rat TMJOA. Such alternations were also revealed by mRNA sequencing of SZC cultured on the softened ECM. Further studies disclosed that reduced ECM stiffness induced decreased PLPP3 on the endoplasmic reticulum (ER), which inhibited mitochondrial fission and respiration via increasing phosphatidic acid (PA) in the mitochondria. Meanwhile, deactivated PI3K-AKT pathway reduced the intra-nuclear translocation of transcriptional factor Cyclic AMP responsive element binding protein 5 (CREB5), which limited PLPP3 expression. Overexpression of PLPP3 alleviated the functional damage of SZC in vitro and the cartilage ECM degradation in vivo. This work displayed the functional impairment of SZC on the softened ECM and the underlying mechanism, as well as suggested PLPP3 as a potential target in the regenerative treatments for TMJOA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.